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Advanced Hodgkin's disease is usually treated with six or
more cycles of combination chemotherapy. Spontaneous re-
gression of the cancer is very rarely reported in patients with
Hodgkin's disease. We present an unusual case of a patient
with Hodgkin's disease who experienced complete remission
with a single cycle of chemotherapy, followed by pneumonia.
The case was a 36-year-old man diagnosed with stage IVB
mixed cellularity Hodgkin's disease in November 2000. After
treatment with one cycle of COPP-ABV (cyclophosphamide,
vincristine, procarbazine, prednisone, doxorubicin, bleomycin,
and vinblastine) chemotherapy without bleomycin, the patient
developed interstitial pneumonia and was cared in the inten-
sive care unit (ICU) for two months. Follow-up chest compu-
terized tomography (CT), performed during the course of ICU
care, revealed markedly improved mediastinal lymphomatous
lesions. Furthermore, follow-up whole body CT and 18-fluoro-
deoxyglucose positron emission tomography showed complete
disappearance of the lymphomatous lesions. Four years later,
the patient is well and without relapse. This report is followed
by a short review of the literature on spontaneous regression
of Hodgkin's disease. To the best of our knowledge, this is the
first case report of spontaneous remission of Hodgkin's disease
in Korea.
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INTRODUCTION
Hodgkin's disease has been diagnosed in appro-
ximately 7 per 100,000 persons annually since
the disorder was first described by Thomas
Hodgkin in 1832.1 Like other malignant diseases,
spontaneous regression of Hodgkin's lymphoma
has been reported as a very rare phenomenon.
Many possible etiologies of this phenomenon have
been proposed, however, the most prevalent view
is that immunologic factors in the host are
responsible. Spontaneous regression of Hodgkin's
disease occurs very rarely compared to non-
Hodgkin's lymphoma. To date, only 15 cases have
been reported in the literature. We report an
unusual case of a patient with Hodgkin's disease
who had complete remission during intensified
care for interstitial pneumonia of an unidentified
organism following one cycle of combination
chemotherapy.
CASE REPORT
The 36-year-old male patient was admitted
through the emergency room on November 30,
2000 with a 15-day history of intermittent spiking
fevers and chills. He had a temperature of 38.1 ,
a pulse rate of 80/min, a respiratory rate of 16/
min, and a blood pressure of 130/80mmHg. There
was no palpable peripheral lymph node enlarge-
ment, hepatomegaly, or splenomegaly. Initial lab-
oratory studies revealed a hemoglobin of 11.0g/
dL, a hematocrit 31.1%, a white blood cell count
4,960/ l (neutrophils, 75.5%; lymphocytes, 12%;μ
monocytes, 7.3%; eosinophils, 0.6%; basophils,
0.5%), and a platelet count 328,000/ l. The C-μ
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reactive protein was 11.9 mg/dL (normal < 0.8
mg/dL). He had an AST/ALT of 98/271 IU/L, total
protein 6.38 g/dL, albumin 3.08 g/dL, total biliru-
bin 0.5 mg/dL, alkaline phosphatase 299 IU/L
(normal 38-115 IU/L), BUN 6.0 mg/dL, and cre-
atinine 0.8 mg/dL. The LDH was 460 IU/L (nor-
mal 225-455 IU/L) with an increased LDH5 iso-
enzyme fraction and β2-microglobulin 3.6 mg/ dL.
The tests for the IgM antibody to herpes simplex
virus (HSV), varicella zoster virus (VZV) and
Epstein-Barr virus (EBV) early antigen were nega-
tive, and the cytomegalovirus (CMV) early anti-
gen was not detected. Microbiologic studies in-
cluding cultures of sputum, urine, stool and blood
were all negative. A posteroanterior chest radio-
graph was normal.
A neck computerized tomography (CT) scan
showed multiple lymphadenopathy (0.5-1.2 cm in
size) on the left level V, the left level II, and the
right level II with well-defined, round contours
without necrotic portions, strongly suggestive of
benign reactive hyperplasia. A chest CT scan
showed multiple areas of lymphadenopathy in the
mediastinum, high and lower right paratracheal,
pretracheal, aortopulmonary window, prevascu-
lar, subcarinal, paraesophageal, right and left
cardiophrenic areas and the right supraclavicular
fossa. The largest lymph node was measured at
3.5×2 cm in the right cardiophrenic area (Fig. 1A).
The lungs were clear, without evidence of abnor-
mal nodules (Fig. 1D). An abdominopelvic CT
scan revealed hepatosplenomegaly with multiple
low-density nodules on the liver and spleen as
well as multiple enlarged lymph nodes in the
aortocaval area, paraaortic area, and along the left
iliac lymphatic chain (4 × 3 × 6 cm), and a conglo-
merated lymph node (3 × 2 cm) on the left renal
hilum. Whole body 18-fluorodeoxyglucose posi-
tron emission tomography (18FDG-PET) showed
massive areas of hot uptake in the mediastinum,
intra-abdominal lymph nodes, liver, and spleen; it
showed multiple areas of hot uptake near the
entire vertebra, bilateral shoulder, rib, left femur,
and pelvic bones, as well as an abnormal lesion
Fig. 1. Serial follow up images of chest CT scans. A. Enlargement of multiple lymph nodes at the paratracheal and
aortopulmonary window was noted at the time of initial diagnosis. B. The enlarged lymph nodes, noted on the initial
CT scan, were found to be markedly improved on the 21st day of hospitalization. C. A CT scan performed nine months
after initial diagnosis showed no abnormalities. D. No abnormalities in the lung parenchyma were found at the time of
diagnosis. E. A CT scan performed at 21th day of hospitalization showed ground glass opacities in the peripheral areas
of both lung parenchyma. F. Although minimal honey combing and reticular patterns remained, the ground glass opacities,
noted at D, were not found with CT nine months after initial diagnosis.
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on the lungs (Fig. 2A). A whole body bone scan
did not show any evidence of bone involvement.
A laparoscopic biopsy of the left iliac lymph node
and liver, performed on the 7th hospital day,
showed mixed celluarity with high contents of
epitheloid histiocytes and a few Reed-Sternberg
giant cells, compatible with Hodgkin's disease
(Fig. 3). Additionally, a bone marrow specimen
showed no infiltration of lymphomatous cells.
The patient was diagnosed with mixed cellu-
larity type, stage IVB Hodgkin's disease. On the
15th hospital day, he received combination che-
motherapy with COPP-ABV but without bleo-
mycin because of insufficient pulmonary function.
One day after initiation of the chemotherapy, the
patient complained of dyspnea on exertion and
even at rest. A chest radiograph revealed slightly
increased peripheral ground-glass opacities with
Fig. 2. Serial follow up images of 18FDG-PET scans. A. The initial 18FDG-PET scan showed massive areas of hot uptake
in the mediastinum, intra-abdominal lymph nodes, spleen, possibly liver, near the entire vertebrae, bilateral shoulder, rib,
and left femur. B. A follow-up
18
FDG-PET scan, performed 3 months after the initial chemotherapy, showed markedly
decreased hot uptakes in the liver, spleen, vertebral bodies and iliac lymph nodes. C. Nine months after initial
chemotherapy, there was no definite abnormal uptake noted on the
18
FDG-PET scan.
Fig. 3. Pathologic features. A. Left iliac lymph node biopsy. Microscopic examination of the specimen showed mixed
cellularity type Hodgkin's disease with high contents of epitheloid histiocytes and a few Reed-Sternberg cells. (H-E stain,
×400). B. Liver biopsy. Reed-Sternberg cells with background reactive cells infiltrated and replaced the liver parenchyma
(H-E stain, ×40).
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peribronchial cuffing in both lower lung fields. He
also had a positive serology for the candida anti-
gen. Therefore, amphotericin B and acyclovir were
administrated in addition to his previous anti-
biotics regimen, composed of cefoperazone/sul-
bactam and amikacin, for treatment of suspected
interstitial pneumonia. Repeat microbiologic
studies did not reveal any pathogens. Virologic
studies including HSV IgM, VZV IgM, CMV IgM,
CMV early antigen, and EBV IgM were all nega-
tive. Two days following the initiation of chemo-
therapy, the patient was transferred to the inten-
sive care unit (ICU) for low PaO2 (68mm Hg). His
chest radiographs, consistent with interstitial
pneumonia, continued to worsen in appearance
despite the addition of trimethoprim/sulfome-
thoxazole and a switch of acyclovir to ganciclovir.
On the 21st hospital day, a chest CT scan, per-
formed to evaluate the abnormal chest radio-
graphic findings, showed ground glass opacities
on the periphery of both lungs with smooth
bronchovascular bundle thickening and interlobu-
lar septal thickening; however, the enlarged
lymph nodes in mediastinum and right supracla-
vicular fossa were markedly improved (Fig. 1B,
1E). The patient's dyspnea did not improve de-
spite vigorous therapy and on the 30th hospital
day the patient was started on mechanical ventila-
tion in the ICU. One day after endotracheal intu-
bation, trimethoprim/sulfomethoxazole was re-
placed with pentamidine because of the former's
bone marrow suppressive effect. During the
period of ICU care and mechanical ventilation, the
patient experienced left foot drop, with sensory
loss due to left peroneal neuropathy, nephrogenic
diabetes inspidus, and pancreatitis secondary to
the pentamidine. However, with maximal conser-
vative care, on the 74th hospital day he improved
enough to be transferred to the general ward and
no longer required mechanical ventilation. Whole
body CT scans were repeated on the 90th hospital
day to assess the lymphadenopathy, noted to be
improved upon follow-up chest CT scan on the
20th hospital day, because the patient had refused
further chemotherapy. Interestingly, follow-up CT
scans of the neck, chest and abdomen-pelvis
showed no definite evidence of lymphadenopathy
in the neck, intrathoracic mediastinum, markedly
decreased lymphadenopathy in the paraaortic
area and the left iliac chain, as well as improved
hepatosplenomegaly with resolution of the
previous low attenuating nodules (Fig. 1C). On
18FDG-PET images there was no evidence of
lymphomatous involvement of the liver, spleen,
iliac, inguinal area or spine, except for a residual
lesion in the upper abdominal lymph node chain
along the inferior vena cava and aorta (Fig. 2B).
These findings were thought to be compatible
with a partial response. Nine months following
the initial chemotherapy, whole body CT (neck,
chest, abdomen and pelvis) scans, 18FDG-PET, and
a whole body bone scan, performed for restaging,
did not show any definite evidence of
lymphomatous lesions, and thus were compatible
with complete remission status (Fig. 2C). On the
103rd hospital day, the patient's tracheotomy site
was sealed. On the 167th hospital day, pulmonary
function tests showed a vital capacity of 39.6%,
FVC of 40.8%, FEV1 of 49.4%, FEV1/FVC of 122,
and DLco of 58.3%. Chest radiography at this time
showed diffuse and coarse reticular changes. The
patient, with the support of his family, decided
not to undergo further chemotherapy and he was
discharged on the 198th day of hospitalization
with slight dyspnea on exertion, but otherwise
feeling well. Four years following hospitalization,
the patient is living well, even climbing up high
mountains, and is without recurrence of
Hodgkin's disease.
DISCUSSION
Spontaneous regression of cancer is defined as
the complete or partial disappearance of a malig-
nant tumor in the absence of or inadequacy of
therapy that is capable of inducing antineoplastic
effects.2 This definition of spontaneous regression
does not necessarily imply a spontaneous cure of
the cancer, because it also applies to cases of in-
complete or temporary regression of cancer. Al-
though spontaneous regression of cancer is uncom-
mon, 761 reports of individual cases and small
case studies have been published between 1900
and 1987.
3,4
Common clinical entities reported to
have shown spontaneous regression include
hypernephroma, malignant melanoma, neuroblas-
toma, leukemia and non-Hodgkin's lymphoma.2
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Spontaneous regression in malignant lymphoma
has been reported primarily in patients with
low-grade non-Hodgkin's lymphoma,5,6 but rare
case reports have described regression in patients
with intermediate or high-grade non- Hodgkin's
lymphoma and Hodgkin's disease.7-9
Untreated Hodgkin's disease has a 5-year sur-
vival rate of less than 5%.10 Spontaneous regres-
sion of Hodgkin's lymphoma is a very rare event;
a search of MEDLINE identified only 15 cases of
spontaneous regression of the disease, with vari-
ous follow-up periods ranging from several
months to eight years.11-16 Of these patients, the
subtypes of Hodgkin's disease were reported in
only eight cases, with the mixed cellularity being
the most frequent subtype (mixed cellularity, 4
cases; lymphocyte predominant, 3 cases; nodular
sclerosis, 1 case). The case described here was also
of the mixed cellularity subtype. Among the 15
reported cases of spontaneous regression, five
cases occurred in children following measles in-
fection; however, all five of these patients still
required treatment with chemotherapy following
the regression.14,15
The etiologies underlying spontaneous remis-
sion remain unclear. The proposed mechanisms to
explain this phenomenon have included the role
of immunological factors, concomitant infections,
hormonal factors, tumor necrosis, angiogenesis
inhibition, apoptosis, elimination of carcinogens,
surgical trauma on the primary tumor, or induc-
tion of differentiation.3,17
Among these possible etiologic factors, immu-
nological mechanisms have been the most fre-
quently used to explain spontaneous regression of
Hodgkin's disease.11,16 Drobynski and Qazi re-
viewed the indirect experimental evidence sup-
porting the notion that host immunological mech-
anisms are important in B cell lymphoma regres-
sion.
17
Ono et al. suggested that highly elevated
natural killing activity might be one of the pos-
sible mechanisms responsible for spontaneous
regression of malignant lymphoma.18 In this
study, the patients with spontaneous regression
had significantly higher natural killing activities
prior to cancer regression than either controls or
patients without regression in the absence of
episodes suggesting viral infection.
Nonspecific stimulation of the immune system
may result in enhancement of host immune re-
sponses against tumors. The temporal association
found between concurrent infections and sponta-
neous remissions of tumor suggests that infection
may stimulate the immune system to induce
tumor regression. Similar immunologic changes
may also play a significant role in the patho-
physiology of post-transplant lymphoproliferative
disease (PTLD). In PTLD, immunosuppressive
agents for prevention of graft rejection can induce
disruption of T cell control of B cell growth,
resulting in the proliferation of Ebstein-Barr virus
infected B cells, which is followed by the develop-
ment of hyperplasia or malignancy.19 This dis-
ruption of the normal immune system can be
recovered by tapering immunosuppressive agents.
In addition, the restored immune system can
identify the abnormal lymphomatous cells and
clear them out.20
It was strongly suggested that the spontaneous
regression observed in our patient was most likely
due to enhanced endogenous immune regulation
from a concomitant unidentified infectious disease
such a viral pneumonia. The immune system in
our patient may have been activated during the
struggle with severe interstitial pneumonia, and
this intensified cellular immunity may be respon-
sible for the spontaneous regression of the tumor.
In addition, various cytokines or toxins associated
with infections may also play a role in mediating
regression.21,22
The experience with this case could support the
possible role of infections as an important etio-
logic factor for spontaneous regression of Hodgkin's
disease via nonspecific ostentation of host im-
munity. However, it is impossible to exclude the
possibility that the tumor cells may have been ex-
tremely sensitive to the chemotherapeutic agents
used. Therefore, the phenomenon of spontaneous
regression should be studied further because a
more precise understanding may make it possible
to harness the host immune system to mediate
tumor regression in neoplastic diseases such as
Hodgkin's disease.
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